What is modafinil and what is its evidence in stimulant use disorders?

• A. A wakefulness-promoting agent with some evidence suggesting reduced cocaine use; not widely approved; used off-label in some cases.
• B. A classic stimulant like amphetamine.
• C. An opioid antagonist.
• D. A benzodiazepine.

Answer: (A)

Modafinil is a wakefulness-promoting medication used for narcolepsy and related sleep disorders, and it has a distinct pharmacologic profile from classic stimulants. In the area of stimulant use disorders, it has been studied as a possible pharmacotherapy because it can enhance alertness without producing the strong euphoria and high abuse potential of drugs like cocaine or methamphetamine.

The best choice captures both aspects: modafinil acts as a wakefulness-promoting agent and there is some evidence from studies suggesting it can reduce cocaine use in certain individuals or help with treatment engagement, though the results are not consistently strong across all trials. It is not widely approved specifically for stimulant use disorders and is often used off-label in some clinical settings.

It isn’t a classic stimulant like amphetamine, so it doesn’t fit that description. It isn’t an opioid antagonist, nor a benzodiazepine, so those labels don’t apply either. In sum, modafinil shows potential in this area but remains not broadly approved and typically used off-label, with evidence indicating modest benefit in some cases.